Eloralintide: molecular data, studies & sources

Molecular formula, weight & structure

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Eloralintide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

22 registered studies matched, 15 currently active or recruiting, 1 with results posted on ClinicalTrials.gov.

By highest phase

Phase 3 · 5Phase 2 · 5Phase 1 · 12

By registry status

Recruiting · 12Completed · 7Active Not Recruiting · 2Not Yet Recruiting · 1

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Eloralintide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

1. Human study · PubMed trial index Compound given to participants

   Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

   Briere DA, Qu H, Lansu K et al. · Molecular metabolism · 2025

   PMID 41109426 · DOI: 10.1016/j.molmet.2025.102271 · Registration NCT05295940

2. Human study · PubMed trial index Compound given to participants

   Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

   Billings LK, Hsia S, Bays H et al. · Lancet (London, England) · 2025

   PMID 41207310 · DOI: 10.1016/S0140-6736(25)02155-5 · Registration NCT06230523

3. Human study · PubMed trial index Compound given to participants

   Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

   Bhattachar S, Tham LS, Tidemann-Miller B et al. · Diabetes, obesity & metabolism · 2026

   PMID 41559929 · DOI: 10.1111/dom.70439

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

1. Research publication · design requires review

   Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.

   Sigalov A, Frishman WH · Cardiology in review · 2026

   PMID 42745233 · DOI: 10.1097/CRD.0000000000001468

Eloralintide supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles